What Is BPC-157? A Complete Guide to the Body Protection Compound
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids. It's derived from a protective protein naturally found in human gastric juice. Since the early 1990s, it has been the subject of numerous animal studies investigating its potential for tissue repair, gut healing, and anti-inflammatory effects.
It is one of the most widely discussed peptides in the biohacking and regenerative medicine communities, and was among the 14 peptides reclassified to Category 1 by the FDA in February 2026.
How Does BPC-157 Work?
BPC-157 appears to work through multiple mechanisms:
- Angiogenesis: Promotes the formation of new blood vessels, which accelerates healing by improving blood supply to damaged tissue.
- Growth factor modulation: Upregulates the expression of growth factors involved in tissue repair, including VEGF and EGF.
- Nitric oxide pathway: Modulates nitric oxide synthesis, which plays a role in blood flow, inflammation, and tissue protection.
- FAK-paxillin pathway: Activates cellular signaling pathways involved in cell migration and wound closure.
The net effect, observed primarily in animal models, is accelerated healing of tendons, ligaments, muscles, bones, and gastrointestinal tissue.
What Is BPC-157 Used For?
Based on published research (predominantly animal studies), BPC-157 has been investigated for:
- Tendon and ligament injuries — Multiple rat studies show accelerated healing of Achilles tendon, MCL, and other connective tissues.
- Gut healing — Protective effects against NSAID-induced gastric damage, inflammatory bowel conditions, and intestinal anastomosis healing.
- Muscle injuries — Accelerated recovery from muscle crush injuries and tears in animal models.
- Bone healing — Some evidence of accelerated fracture healing.
- Neuroprotection — Preliminary evidence of protective effects against certain neurotoxins.
What Are the Risks?
It's important to be honest about the limitations:
- Most research is in animals. There are very few published human clinical trials for BPC-157. The majority of evidence comes from rat and mouse studies.
- Long-term safety is unknown. No long-term human safety data exists.
- Potential drug interactions. BPC-157 may interact with blood pressure medications and other drugs that affect the nitric oxide pathway.
- Injection site reactions. Redness, swelling, and discomfort at the injection site are commonly reported.
- Quality concerns. Prior to the 2026 reclassification, most BPC-157 was sourced from unregulated suppliers. Purity and dosing accuracy varied widely.
Current Legal Status
As of February 2026, BPC-157 has been reclassified from Category 2 to Category 1 by the FDA. This means:
- Licensed compounding pharmacies can legally prepare BPC-157.
- A physician prescription is required.
- It is not FDA-approved as a drug — it is available through the compounding pathway.
- It remains illegal to sell as a consumer product without a prescription.
This reclassification was part of a broader move by HHS to restore access to 14 peptides that had been restricted in 2023.
The Bottom Line
BPC-157 is one of the most promising peptides for tissue repair based on animal research. The 2026 reclassification has made it legally accessible through legitimate medical channels for the first time in years. However, human clinical data remains limited, and anyone considering BPC-157 should work with a qualified healthcare provider who can monitor their response and adjust dosing appropriately.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.